Eric Huselton

Eric Huselton

Auto-generated profile, based on publicly available information

Eric Huselton

Division of Hematology & Oncology, Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elwood Ave, Rochester, NY 14624, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
KLKah Poh Loh
Kah Poh Loh
CSChandrika Sanapala
Chandrika Sanapala
EWErin Elizabeth Watson
Erin Elizabeth Watson
MJMarielle Jensen-Battaglia
Marielle Jensen-Battaglia
MJMichelle C. Janelsins
Michelle C. Janelsins
KMKaren Mustian
Karen Mustian
Many older patients with myeloid neoplasms experience treatment-related toxicities. We previously demonstrated that a home-based, progressive aerobic walking and resistance exercise program (EXCAP) improved physical and psychological outcomes in patients with cancer. However, older patients have more difficulty adhering to exercise than younger patients. Reasons may include low motivation, difficulty with transportation, and limited access to exercise professionals. To improve exercise adherence, we integrated a mobile app with EXCAP (GO-EXCAP) and assessed its feasibility and usability in a single-arm pilot study among older patients with myeloid neoplasms undergoing outpatient chemotherapy. GO-EXCAP intervention lasts for 2 cycles of treatment, and the primary feasibility metric was data reporting on the app. Usability was evaluated via the system usability scale (SUS). Patients were interviewed at mid and postintervention to elicit their feedback, and deductive thematic analysis was applied to the transcripts. Twenty-five patients (mean age, 72 years) were recruited. Recruitment and retention rates were 64% and 88%, respectively. Eighty-two percent (18/22) of patients entered some exercise data on the app at least half of the study days, excluding hospitalization (a priori, we considered 70% as feasible). Averaged daily steps were 2848 and 3184 at baseline and after intervention, respectively. Patients also performed resistance exercises 26.2 minutes per day, 2.9 days per week at low intensity (rate of perceived exertion 3.8/10). Usability was above average (SUS, 70.3). In qualitative analyses, 3 themes were identified, including positive experience with the intervention, social interactions, and flexibility. The GO-EXCAP intervention is feasible and usable for older patients with myeloid neoplasms undergoing outpatient chemotherapy. This trial was registered at www.clinicaltrials.gov as #NCT04035499.

1 October 2018 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
EHEric Huselton
Eric Huselton
MSMichael Slade
Michael Slade
KTKathryn M. Trinkaus
Kathryn M. Trinkaus
JDJohn F DiPersio
John F DiPersio
PWPeter Westervelt
Peter Westervelt
RRRizwan Romee
Rizwan Romee
T cell replete HLA-haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide was originally described using a reduced-intensity conditioning (RIC) regimen. Given that myeloablative conditioning (MAC) is more effective at preventing disease relapse, we compared outcomes of patients receiving MAC and RIC regimens. We evaluated overall survival (OS), disease-free survival (DFS), relapse, nonrelapse mortality (NRM), and graft-versus-host disease (GVHD) of 148 patients that underwent haplo-HCT with either MAC (n = 61) or RIC (n = 87). Propensity score adjustment (PSA) was used to balance baseline characteristics between groups and more effectively compare outcomes based on conditioning intensity. After the PSA analysis, relapse was significantly decreased with MAC (hazard ratio [HR], .47; 95% confidence interval [CI], .31 to .70), but was associated with higher NRM (HR, 1.74; 95% CI, 1.13 to 2.67). OS and DFS were not significantly different between groups (HRs for MAC versus RIC were .87 [95% CI, .64 to 1.18] and .90 [95% CI, .68 to 1.18] for OS and DFS, respectively). Rates of acute and chronic GVHD were not significantly different between groups. This analysis suggests that both MAC and RIC regimens are effective in haplo-HCT and that MAC regimens may result in less relapse in selected patients. These results need to be verified in a larger registry study.

1 July 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MSMark A. Schroeder
Mark A. Schroeder
MFMark A. Fiala
Mark A. Fiala
EHEric Huselton
Eric Huselton
Michael CardoneMichael Cardone
Michael Cardone
SJSavina Jaeger
Savina Jaeger
RVRavi Vij
Ravi Vij
Purpose: Pegylated liposomal doxorubicin (PLD) combined with bortezomib is an effective salvage regimen for relapsed refractory multiple myeloma (RRMM). Carfilzomib, a second-generation proteasome inhibitor, has clinical efficacy even among bortezomib-refractory patients. Patients and Methods: We performed a phase I/II trial of carfilzomib, PLD, and dexamethasone (KDD) with the primary endpoints being safety and efficacy (NCT01246063). Twenty-three patients were enrolled in the phase I portion and the MTD of carfilzomib was determined to be 56 mg/m2 (days 1, 2, 8, 9, 15, and 16) when combined with PLD (30 mg/m2 on day 8) and dexamethasone (20 mg on days 1, 2, 8, 9, 15, and 16). Seventeen additional patients were enrolled in the phase II portion. Results: KDD was determined to be well tolerated with the only common grade 3/4 nonhematologic adverse events of infection. Grade 3/4 hematologic toxicity included lymphopenia (63%), thrombocytopenia (40%), anemia (40%), and neutropenia (28%). In the cohort of patients treated at the MTD, where median prior therapies were 2% and 42% were refractory to bortezomib, the overall response rate was 83% (20/24) with 54% (13/24) having a very good partial response or better. The median progression-free survival was 13.7 months (95% CI, 5.0–21.7). Conclusions: This trial is the first to report outcomes using a triplet regimen of high-dose carfilzomib. KDD was well tolerated and appears efficacious in RRMM. Additional study is needed to more precisely determine patient outcomes with this regimen and its utility compared with other carfilzomib containing salvage regimens.

1 November 2021 in Leukemia Research
Verified
Journal Article
Closed access
EHEric Huselton
Eric Huselton
MRMichael P. Rettig
Michael P. Rettig
KCKirsten Campbell
Kirsten Campbell
ACAmanda F. Cashen
Amanda F. Cashen
JDJohn F. DiPersio
John F. DiPersio
PWPeter Westervelt
Peter Westervelt

10 September 2022 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
MLMarissa LoCastro
Marissa LoCastro
CSChandrika Sanapala
Chandrika Sanapala
JMJason H. Mendler
Jason H. Mendler
SNSally Norton
Sally Norton
RBRachelle Bernacki
Rachelle Bernacki
KLKah Poh Loh
Kah Poh Loh

28 April 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
MLMarissa LoCastro
Marissa LoCastro
CSChandrika Sanapala
Chandrika Sanapala
JMJason H. Mendler
Jason H. Mendler
SNSally Norton
Sally Norton
RBRachelle Bernacki
Rachelle Bernacki
KLKah Poh Loh
Kah Poh Loh
Older patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) experience intense inpatient health care at the end-of-life stage. Early advance care planning may improve care at the end of life for patients with AML or MDS. The Serious Illness Care Program (SICP) is a multicomponent, communication intervention developed to improve conversations about values for patients with serious illnesses. The SICP has been shown to improve the quality and frequency of advance care planning discussions. We adapted the SICP for delivery via telehealth to older patients with AML or MDS. We conducted a single-center qualitative study of 45 participants (25 clinicians, 15 older patients with AML or MDS, and 5 caregivers). Participants, whether clinicians, patients, or caregivers, agreed that the SICP would help older patients with AML or MDS to share their personal values with their care team. Four qualitative themes emerged from our data: (1) serious illness conversations can be conducted via telehealth, (2) older patients have limited experience using technology but are willing and able to learn, (3) patients feel that serious illness conversations will help them understand their AML or MDS diagnosis and prognosis better, and (4) serious illness conversations should be common and routine, not extraordinary. The adapted SICP may provide older patients with AML or MDS an opportunity to share what matters most to them with their care team and may assist oncologists in aligning patient care with patient values. The adapted SICP is the subject of an ongoing single-arm pilot study at the Wilmot Cancer Institute (clinicaltrials.gov identifier: NCT04745676).